Compare Abeona Therapeutics Inc (ABEO) vs Alibaba Group (BABA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Alibaba Group — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Alibaba Group trades at $108.88 (market cap $234.34B). The key difference: Alibaba Group is far larger — about 627.7× Abeona Therapeutics Inc's market cap, and Alibaba Group pays a 1.07% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BABA | |
|---|---|---|
Market Cap | $373.32M | $234.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $189.34 |
52-Week Low | $4.17 | $94.83 |
Enterprise Value | $228.22M | $229.16B |
Volume | — | 18,069,938 |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Alibaba (BABA) trades at $98.14, up 2.08% today, but remains in a bearish technical trend with recent earnings misses. The company reported strong revenue growth to $996.35B in 2025 and a net income margin of 13.05%, yet faces headwinds from regulatory investigations and a $600M DOJ settlement. Analyst consensus is overwhelmingly bullish with an $195 price target, highlighting a significant discount to intrinsic value despite near-term challenges.
The stock presents a contrarian opportunity with attractive valuations (P/E 15.13, P/S 1.56) amid pessimism. Key risks include ongoing legal probes, AI competition, and macroeconomic pressures. Upside depends on earnings recovery and resolution of regulatory overhangs, making it a high-risk, high-reward play for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Alibaba Group
Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.
Read more on BABA →
